Últimas noticias sobre Nurix Therapeutics (NASDAQ:NRIX) Bolsa

Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Nurix Therapeutics Inc

Citigroup analyst Steven Enders downgrades Intapp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTA#NASDAQ">INTA</a>) from Buy to Neutral and lowers the price target from $87 to $78.

News

Downgrades

Price Target

Analyst Ratings

INTA

Citigroup Downgrades Intapp to Neutral, Lowers Price Target to $78

WIIM

Taiwan Semiconductor shares are trading higher after the company reported better-than-expected Q4 EPS and revenue, and issued Q1 revenue guidance above estimates.

Morgan Stanley analyst Chris Quintero upgrades OneStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OS#NASDAQ">OS</a>) from Equal-Weight to Overweight and maintains the price target from $37 to $37.

Upgrades

Morgan Stanley Upgrades OneStream to Overweight, Maintains Price Target to $37

Earnings

Bank of America Q4 Provision For Credit Losses $1.5B

Chinese EV maker Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) said on Thursday that it has surpassed 200,000 deliveries of its L6 vehicle in less than nine months of its launch. 
What Happened: Li Auto announced the L6 five-seater SUV with a starting price of about 249,800 yuan in April and commenced deliveries in the same month. 
Less than nine months since launch, the company has already delivered over 200,000 units of the vehicle, the company said, likely due to its low price point. 
Tesla&#8217;s Model Y mass-market SUV, in comparison, starts at 263,500 yuan in China for the base variant. Tesla&#8217;s lower-priced Model 3 sedan, meanwhile, starts at 235,500 yuan. 
Why It Matters: Li Auto started volume production in November 2019 and as of the end of December, its cumulative deliveries stood at 1,133,872 units. 
In 2024 alone, the company delivered <a href="https://www.benzinga.com/25/01/42758540/us-listed-chinese-ev-startups-clock-delivery-growth-in-december-li-auto-tops-the-chart-mona-m03-spurs-xpeng-nios-onvo-breaches-10000-monthly-delivery-milestone">over 500,500 vehicles</a>, taking up a significant portion of the competitive Chinese EV market, and marking a growth of 33% year-on-year. 
The company&#8217;s current vehicle lineup includes its Li MEGA family MPV as well as multiple SUVs including the L9, L8, L7, and L6. 
Price Action: NASDAQ-listed shares of Li Auto closed down 2% at $21.88 on Wednesday. The stock is down 8.9% year-to-date, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>. 
Li Auto has a consensus price target of&nbsp;$34.86&nbsp;based on the ratings of&nbsp;11&nbsp;analysts tracked by Benzinga, and a consensus &#8220;buy&#8221; rating. 
The three most recent <a href="https://www.benzinga.com/quote/LI/analyst-ratings">analyst ratings</a> were released by Barclays, Macquarie, and Citigroup in November, October, and September, respectively. With an average price target of $31.2 between Barclays, Macquarie, and Citigroup, there&#8217;s an implied 42.47% upside for Li Auto from these most recent analyst ratings.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/LI/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="389" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16063434/image-106-1024x389.png" alt="" class="wp-image-736514" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16063434/image-106-1024x389.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16063434/image-106-300x114.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16063434/image-106-768x292.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16063434/image-106.png 1193w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43020700/nhtsa-closes-safety-probe-into-gm-cruise-robotaxis-weeks-after-it-ceased-operations" target="_blank" rel="noreferrer noopener">NHTSA Closes Safety Probe Into GM Cruise Robotaxis Weeks After It Ceased Operations</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Tesla Rival Li Auto Says L6 SUV Deliveries Crossed 200,000 Units In Less Than 9 Months Of Launch

Bank of America shares are trading higher following better-than-expected Q4 financial results.

Citigroup analyst Steven Enders upgrades BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) from Neutral to Buy and maintains the price target from $73 to $73.

Citigroup Upgrades BlackLine to Buy, Maintains Price Target to $73

U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $1.05 by 1.9 percent. This is a 8.08 percent increase over earnings of $0.99 per share from the same period last year.

Earnings Beats

U.S. Bancorp Q4 2024 Adj EPS $1.07 Beats $1.05 Estimate

Bank of America Q4 Net Interest Income Up 3%, Total Investment Banking Fees Up 44%, Sales And Trading Revenue Up 13%, Consumer Banking Revenue Up 3%, Avg. Deposits Down 2%

Bank of America Q4 2024 GAAP EPS $0.82 Beats $0.77 Estimate, Revenue Net Of Interest Expense $25.347B

Citigroup analyst Stephen Trent downgrades Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) from Neutral to Sell and lowers the price target from $31.5 to $29.5.

Citigroup Downgrades Southwest Airlines to Sell, Lowers Price Target to $29.5

Needham analyst Chris Pierce reiterates Sonic Automotive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) with a Buy and maintains $74 price target.

Reiteration

Needham Reiterates Buy on Sonic Automotive, Maintains $74 Price Target

Citigroup analyst Gustavo Schroden downgrades StoneCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) from Buy to Neutral and lowers the price target from $19 to $9.

STNE

Citigroup Downgrades StoneCo to Neutral, Lowers Price Target to $9

Needham analyst Chris Pierce maintains CarGurus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARG#NASDAQ">CARG</a>) with a Buy and raises the price target from $39 to $45.

CARG

Needham Maintains Buy on CarGurus, Raises Price Target to $45

Citigroup analyst Gustavo Schroden downgrades PagSeguro Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAGS#NYSE">PAGS</a>) from Buy to Neutral and lowers the price target from $17 to $7.

PAGS

Citigroup Downgrades PagSeguro Digital to Neutral, Lowers Price Target to $7

Needham analyst James Ricchiuti reiterates Proto Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NYSE">PRLB</a>) from Hold to Hold.

PRLB

Needham Reiterates Hold on Proto Labsto Hold

Goldman Sachs analyst Patrick Creuset maintains GXO Logistics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GXO#NYSE">GXO</a>) with a Neutral and lowers the price target from $63 to $54.

Goldman Sachs Maintains Neutral on GXO Logistics, Lowers Price Target to $54

Guidance

Commodities

Markets

General

NGVT

Ingevity Announced Preliminary 2024 Sales Of Approximately $1.4B Versus Consensus Of $1.414B, Adjusted EBITDA Of Approximately $360M And Free Cash Flow Of Greater Than $40M

Needham analyst Ryan MacDonald reiterates Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Buy and maintains $43 price target.

ZETA

Needham Reiterates Buy on Zeta Global Holdings, Maintains $43 Price Target

Battery materials company Vianode has secured a deal with General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) to supply high-performance anode <a target="_blank" href="https://www.vianode.com/news/vianode-signs-usd-multi-billion-long-term-supply-agreement-for-ev-battery-grade-anode-graphite-with-gm" rel="noreferrer noopener">graphite </a>solutions.
The master supply agreement, which has a multi-billion value for Vianode, marks a significant step forward in bolstering the North American battery and EV supply chain.
The agreement encompasses the development of large-scale manufacturing capabilities and the supply of synthetic anode graphite through 2033.
The agreement will support GM&#8217;s battery cell manufacturing joint venture with LG Energy Solution, Ultium Cells LLC, and its future EV developments.
The graphite will be produced at Vianode&#8217;s large-scale, IRA-compliant plant in North America, with operations beginning in 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/43020700/nhtsa-closes-safety-probe-into-gm-cruise-robotaxis-weeks-after-it-ceased-operations" rel="noreferrer noopener">NHTSA Closes Safety Probe Into GM Cruise Robotaxis Weeks After It Ceased Operations</a>
&#8220;Vianode&#8217;s advanced battery materials enable cost-efficient batteries and EVs with better performances and a fraction of the carbon emissions of conventional technologies,&#8221; said Vianode CEO Burkhard Straube.
Vianode&#8217;s synthetic anode graphite presents a greener option compared to natural graphite, cutting CO2 emissions by 90% during manufacturing.
By 2030, Vianode aims to provide enough material to power 3 million EVs each year, with plans to expand its production capacity across North America and Europe.
As the largest component in lithium-ion batteries, anode graphite plays a vital role in the performance and energy storage of electric vehicles.
&#8220;This project will help advance our battery technology and drive greater value to our customers,&#8221; said Jeff Morrison, senior vice president of Global Purchasing and Supply Chain at General Motors.
Price Action: GM shares closed higher by 1.49% at $51.70 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42939311/wayfair-expands-google-cloud-partnership-to-tap-ai-for-cost-cuts-and-efficiency" target="_blank" rel="noreferrer noopener">Wayfair Expands Google Cloud Partnership To Tap AI For Cost Cuts And Efficiency</a></li>
</ul>
Photo via Shutterstock.

GM, Vianode Strike Multi-Billion Anode Graphite Supply Deal: Details

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $34.0...

Nurix Therapeutics (NRIX) Receives a Buy from Stifel Nicolaus

In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price t...

Oppenheimer Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

Barclays analyst Peter Lawson assigned a Buy rating to Nurix Therapeutics (NRIX – Research Report) today and set a price target of $31.00. The comp...

Nurix Therapeutics (NRIX) Receives a Buy from Barclays

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a pric...

Nurix Therapeutics (NRIX) Gets a Buy from Piper Sandler

Tracking Baker Brothers Portfolio - Q3 2024 Update

Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration has granted Fast Track designation for NX-5948, a highly selective d...

Nurix Therapeutics receives U.S. FDA Fast Track designation for NX-5948

Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report). The ...

Truist Financial Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

Barclays analyst Peter Lawson maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) today and set a price target of $31.00. The co...

Barclays Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)

ABCL

ACAD

ALGS

ALKS

ARGNF

ARGX

AVTE

BCYC

BEIGF

BGNE

BMEA

CERS

DNLI

EWTX

GILD

GLUE

HOOK

IGMS

IMCR

IMTX

INCY

INSM

KALA

KNSA

KYMR

MDGL

NRIX

RARE

REPL

RVMD

RYTM

SGMT

SMMT

SNYNF

STOK

TCRX

TRDA

TSVT

VTVT

Press Releases

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Presentations at the 66th American Society of Hematology (ASH) Annual Meeting

Health Care

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Legal

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

Comments

Nurix Therapeutics

Noticias

Últimas noticias sobre Nurix Therapeutics (NASDAQ:NRIX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL